Literature DB >> 17634376

Annonacin, a natural mitochondrial complex I inhibitor, causes tau pathology in cultured neurons.

Myriam Escobar-Khondiker1, Matthias Höllerhage, Marie-Paule Muriel, Pierre Champy, Antoine Bach, Christel Depienne, Gesine Respondek, Elizabeth S Yamada, Annie Lannuzel, Takao Yagi, Etienne C Hirsch, Wolfgang H Oertel, Ralf Jacob, Patrick P Michel, Merle Ruberg, Günter U Höglinger.   

Abstract

A neurodegenerative tauopathy endemic to the Caribbean island of Guadeloupe has been associated with the consumption of anonaceous plants that contain acetogenins, potent lipophilic inhibitors of complex I of the mitochondrial respiratory chain. To test the hypothesis that annonacin, a prototypical acetogenin, contributes to the etiology of the disease, we investigated whether annonacin affects the cellular distribution of the protein tau. In primary cultures of rat striatal neurons treated for 48 h with annonacin, there was a concentration-dependent decrease in ATP levels, a redistribution of tau from the axons to the cell body, and cell death. Annonacin induced the retrograde transport of mitochondria, some of which had tau attached to their outer membrane. Taxol, a drug that displaces tau from microtubules, prevented the somatic redistribution of both mitochondria and tau but not cell death. Antioxidants, which scavenged the reactive oxygen species produced by complex I inhibition, did not affect either the redistribution of tau or cell death. Both were prevented, however, by forced expression of the NDI1 nicotinamide adenine dinucleotide (NADH)-quinone-oxidoreductase of Saccharomyces cerevisiae, which can restore NADH oxidation in complex I-deficient mammalian cells and stimulation of energy production via anaerobic glycolysis. Consistently, other ATP-depleting neurotoxins (1-methyl-4-phenylpyridinium, 3-nitropropionic, and carbonyl cyanide m-chlorophenylhydrazone) reproduced the somatic redistribution of tau, whereas toxins that did not decrease ATP levels did not cause the redistribution of tau. Therefore, the annonacin-induced ATP depletion causes the retrograde transport of mitochondria to the cell soma and induces changes in the intracellular distribution of tau in a way that shares characteristics with some neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17634376      PMCID: PMC6672878          DOI: 10.1523/JNEUROSCI.1644-07.2007

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  49 in total

1.  Possible relation of atypical parkinsonism in the French West Indies with consumption of tropical plants: a case-control study. Caribbean Parkinsonism Study Group.

Authors:  D Caparros-Lefebvre; A Elbaz
Journal:  Lancet       Date:  1999-07-24       Impact factor: 79.321

2.  Morphological evidence of the inhibitory effect of taxol on the fast axonal transport.

Authors:  T Nakata; H Yorifuji
Journal:  Neurosci Res       Date:  1999-11       Impact factor: 3.304

Review 3.  Mitochondria as the central control point of apoptosis.

Authors:  S Desagher; J C Martinou
Journal:  Trends Cell Biol       Date:  2000-09       Impact factor: 20.808

4.  Modulation of oxidative phosphorylation of human kidney 293 cells by transfection with the internal rotenone-insensitive NADH-quinone oxidoreductase (NDI1) gene of Saccharomyces cerevisiae.

Authors:  B B Seo; A Matsuno-Yagi; T Yagi
Journal:  Biochim Biophys Acta       Date:  1999-05-26

Review 5.  Tau pathology: a marker of neurodegenerative disorders.

Authors:  A Delacourte; L Buée
Journal:  Curr Opin Neurol       Date:  2000-08       Impact factor: 5.710

6.  Use of the NADH-quinone oxidoreductase (NDI1) gene of Saccharomyces cerevisiae as a possible cure for complex I defects in human cells.

Authors:  B B Seo; J Wang; T R Flotte; T Yagi; A Matsuno-Yagi
Journal:  J Biol Chem       Date:  2000-12-01       Impact factor: 5.157

7.  Mitochondrial dysfunction in cybrid lines expressing mitochondrial genes from patients with progressive supranuclear palsy.

Authors:  R H Swerdlow; L I Golbe; J K Parks; D S Cassarino; D R Binder; A E Grawey; I Litvan; J P Bennett; G F Wooten; W D Parker
Journal:  J Neurochem       Date:  2000-10       Impact factor: 5.372

8.  Deficit of brain and skeletal muscle bioenergetics in progressive supranuclear palsy shown in vivo by phosphorus magnetic resonance spectroscopy.

Authors:  P Martinelli; C Scaglione; R Lodi; S Iotti; B Barbiroli
Journal:  Mov Disord       Date:  2000-09       Impact factor: 10.338

Review 9.  Tau-positive glial inclusions in progressive supranuclear palsy, corticobasal degeneration and Pick's disease.

Authors:  T Komori
Journal:  Brain Pathol       Date:  1999-10       Impact factor: 6.508

10.  Tau regulates the attachment/detachment but not the speed of motors in microtubule-dependent transport of single vesicles and organelles.

Authors:  B Trinczek; A Ebneth; E M Mandelkow; E Mandelkow
Journal:  J Cell Sci       Date:  1999-07       Impact factor: 5.285

View more
  70 in total

Review 1.  The Alzheimer's disease mitochondrial cascade hypothesis.

Authors:  Russell H Swerdlow; Jeffrey M Burns; Shaharyar M Khan
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

2.  Loss of the m-AAA protease subunit AFG₃L₂ causes mitochondrial transport defects and tau hyperphosphorylation.

Authors:  Arun Kumar Kondadi; Shuaiyu Wang; Sara Montagner; Nikolay Kladt; Anne Korwitz; Paola Martinelli; David Herholz; Michael J Baker; Astrid C Schauss; Thomas Langer; Elena I Rugarli
Journal:  EMBO J       Date:  2014-03-28       Impact factor: 11.598

3.  Dual mTORC1/mTORC2 blocker as a possible therapy for tauopathy in cellular model.

Authors:  Mohamed Salama; Mahmoud Elhussiny; Alshimaa Magdy; Ahmed G Omran; Aziza Alsayed; Ramy Ashry; Wael Mohamed
Journal:  Metab Brain Dis       Date:  2017-10-27       Impact factor: 3.584

Review 4.  The neurodegenerative mitochondriopathies.

Authors:  Russell H Swerdlow
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

Review 5.  The role of mitochondria in neurodegenerative diseases.

Authors:  Massimiliano Filosto; Mauro Scarpelli; Maria Sofia Cotelli; Valentina Vielmi; Alice Todeschini; Valeria Gregorelli; Paola Tonin; Giuliano Tomelleri; Alessandro Padovani
Journal:  J Neurol       Date:  2011-05-22       Impact factor: 4.849

6.  IACS-010759, a potent inhibitor of glycolysis-deficient hypoxic tumor cells, inhibits mitochondrial respiratory complex I through a unique mechanism.

Authors:  Atsuhito Tsuji; Takumi Akao; Takahiro Masuya; Masatoshi Murai; Hideto Miyoshi
Journal:  J Biol Chem       Date:  2020-04-14       Impact factor: 5.157

Review 7.  Current perspective of mitochondrial biology in Parkinson's disease.

Authors:  Navneet Ammal Kaidery; Bobby Thomas
Journal:  Neurochem Int       Date:  2018-03-14       Impact factor: 3.921

Review 8.  Microtubule Destabilization Paves the Way to Parkinson's Disease.

Authors:  D Cartelli; G Cappelletti
Journal:  Mol Neurobiol       Date:  2016-10-18       Impact factor: 5.590

Review 9.  Neurodegenerative diseases: neurotoxins as sufficient etiologic agents?

Authors:  Christopher A Shaw; Günter U Höglinger
Journal:  Neuromolecular Med       Date:  2007-11-06       Impact factor: 3.843

Review 10.  Parkinson's disease and mitochondrial complex I: a perspective on the Ndi1 therapy.

Authors:  Mathieu Marella; Byoung Boo Seo; Takao Yagi; Akemi Matsuno-Yagi
Journal:  J Bioenerg Biomembr       Date:  2009-12       Impact factor: 2.945

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.